LaserStock29 wrote: that's a half truth and you know it.. back in 1993 the main problems facing PDT keeping the science 'immatutre' to pharma were these factors
1.The ability to measure light
2 The photodynamic uptake to tissue
3. Organ safety to the muscle layer
4. durable responses (subject to the first three points above)
(Photofrin had 60%) efficacy
8 years and they've absolutely shown without a doubt.
1. They can measure light (with the computer automated) Optimized calculations
2. Tissue update is at an extremely favored ratio
3. Safety with multiple (2) doses and no side effects (that would compromise the bladder)
Those three factors alone should of moved the price from an immature .30c from 2014 to at least 100m cap cruising.
This used to be talked about
14 day Urine test detect the cells
30 day Xray for muscle layer damage
90 day cystoscopy (the real test to take a look inside for damage)
180 day 2nd treatment.
etc..
This is an absolute joke and yes it's about getting PAID.
sciencefirst....... I agree with you on the BTD/AA by EOY stuff.. it does look favorable...
I just need to see proof that no f*c*e*y is afoot with the financing.
Cheers.
It's been a long ride.. and we're being ridden again..
gebremeskel wrote: TLD1433 is not a done deal yet. Everybody is analysing and re-analysing the data to try and make the case that Theralase has outdone all possible NMIBC competition and BTD & AA are just around the corner. But we don't have the data yet. And no amount of hand-wringing about "getting paid" is going to change anything. If the numbers are good we get BTD & AA and we're all happy campers. If not we wait a couple more years for the end of the trial while our investment gets more diluted and rutherrin trials move off into the vapour. Nothing is proven until we get substantial durable response rates for a significant number of patients. That's someting the brutes in big pharma will understand.
Rumpl3StiltSkin wrote: I dunno Laser,
1433/TLT has proven itself to the investors on this board. Seems pharmas still have their heads up their butts on this, thinking instead about pills and immuno-therapy and vaccines. Other traditional drug approaches that usually only pan out 15% of the time.
TLT is soo close isn't it? It is maddening! :-) They may show a real threat against Covid this year. They
should show the world next year that Rutherrin/PDT is the way forwards for Cancer.
LaserStock29 wrote: Legit62 wrote: Totally agree Infinity, i think we are just at the beginning of knowing what TLD1433 can really do, i am a long holder and have accumulated many shares like all of you long holders and am also hoping we dont sell ourselves short, also think we are within 6 months of BTD and AA, am curious to see what is presented on the 27TH and at AGM, also would like to know more about The Li Ka Shing relationship, cause as Skyes1 says , he believes this holds the key to our moving foward .
Osmium molecules 2017 Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is committed to expanding our Phase Ib clinical research program to include new oncological targets, using both our Ruthenium (TLD-1433) and Osmium ((TLD-1822, TLD-1824 and TLD-1829) based PDCs. We look forward to presenting this research to the international scientific and medical communities.” 1633 15% more gbm Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro stated that, “TLD-1633 is a natural progression of the research work completed by our research labs in the development of TLD-1433. TLD-1633 has shown even stronger safety and efficacy in our labs than TLD-1433, and I am delighted to work with Theralase to optimize and expand their licenced PDC program, as we embark on additional cancer indications.” Were you guys asleep for 5 years......
This whole thing..... oh the TLD-1433... we're just at the beginning.......... NO... we are at the END of Tld-1433........
It's time to get PAID for Bladder and move into Ruthenium and other molecules...
Do a massive licensing or buyout for ACT and the technology.......
Photodynamic therapy has proven it's 'matured' to become attractive to big pharma.